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Introduction
Radical prostatectomy (RP) is considered to be the treatment of choice for men with clinically localised prostate cancer with a life expectancy of >10 years [1] .
(p < 0.001), operating time (p < 0.001), mean length of hospital stay (p < 0.001) and duration of catheter (p < 0.001) between the 3 groups as the series progressed. The two most important factors predictive of positive surgical margins (PSM) at RRP were the initial prostate specific antigen (PSA) and tumor stage at diagnosis. The overall PSM rate was 26.7%. For T2/T3 tumors the incidence of PSM reduced as the series progressed (Group 1-22%, Group 2-32% and Group 3-26%). The incidence of major complications i.e. grade Clavien-Dindo system score ≤ III was 2% (6/300). Conclusion: RRP is a safe procedure with low morbidity. As surgeons progress through the learning curve peri-operative parameters and oncological outcomes improve. This learning curve is not affected by the introduction of a fellowship-training programme. Using a carefully structured mentored approach, RRP can be safely introduced as a new procedure without compromising patient outcomes.
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The goal of RP is to achieve the 'trifecta' of cancer cure, while recovering normal urinary continence and erectile function. There has been a rapid increase in the number of centres performing robotic radical prostatectomy (RRP) worldwide over the past 10 years with a further number of urologists incorporating RRP into practice [2] . In current literature the benefits of a RRP versus laparoscopic and open RP continue to be evaluated in terms of clinical benefit to patients, the high cost of implementing RRP and the need for surgeons to acquire new robotic skills [3] . Current data indicates that a RRP has lower perioperative morbidity and a reduced risk of a positive surgical margin (PSM) compared with laparoscopic prostatectomy [3] . RRP was popularized by Dr Menon from the Vattikutti Foundation in 1999 [4] . With the introduction of the RRP programme in 2001 by Menon and the further comparison studies of RRP and open RP confirm that the RRP is superior in terms in blood loss, post-operative pain score, hospital stay and percentage discharged within 24 hours [5] .
Although there is no official screening policy for prostate cancer in the UK, the incidence of prostate cancer has risen dramatically in the prostate specific antigen (PSA) era. At present approximately 25% of men with PSA levels above threshold will have cancer detected on biopsy, 38 with 37,051 men being registered with the diagnosis in the UK during 2008 [6] . As a consequence of earlier detection there has been considerable stage migration and the majority of patients now present with clinically localized disease [7] . Many patients with clinically localized prostate cancer now choose RP as their preferred treatment modality. The number of RPs performed in England and Wales has increased 19-fold from 164 in 1991 to 3,070 in 2004 [8] . In a study reported by Hanchanale et al. [9] , the number of RP performed in England increased annually from 972 (1998-1999) to 3,092 (2004-2005) . During the same period the number of laparoscopic radical prostatectomy (LRP) increased from 2 to 257. Recent evidence suggests that RRP is becoming the method of choice for the surgical removal of the prostate [10] , with a substantial proportion of RP performed this way in the UK in 2011. The number of prostatectomies is rising markedly in the UK as between 2008/09 and 2009/10 the total increased from 4,100 to 4,900 -a 20% increase.
It is accepted that greater surgical experience is associated with improved functional and oncological outcomes after RP [8] [9] [10] . As a RRP is a relatively new technique in the UK, like any new technique there is an associated learning curve. The learning curve of an individual cancer centre is establishing progression with the technique in terms of outcomes (operating time, console time, blood loss, hospital stay, complications), oncological outcomes (PSM, recurrence) and functional outcomes (continence rates, erectile dysfunction rates) [11] [12] [13] .
Introducing a new procedure such as RRP to a department where it has never been previously performed brings significant challenges. The most important issue is to protect patients from poor outcomes while the surgeon and his team progresses through the learning curve and familiarises themselves with the technique. The British Association of Urological Surgeons has published guidelines on training and mentorship in LRP [14] . Further complexities arise when having completed training in RRP, the lead surgeon, facilitates service development within a department for training additional surgeons and fellows. The former lead surgeon becomes the mentor and trainer to another surgeon learning RRP. The trained surgeons then train the robotic fellow. Here the unique challenge is to maintain safety and improve results and outcomes whilst mentoring a colleague and fellow through a new learning curve.
We present the results of the first 300 cases of transperitoneal LRP performed in our department by a team of 3 surgeons, focussing on peri-operative outcomes, complications and oncological results using a carefully planned mentored approach.
Patients and Methods
Between November 2008 and August 2012, a total of 300 consecutive transperitoneal LRPs were performed in our unit by 3 surgeons. A fellowship-training programme was introduced in August 2011 which is now recognized by the Royal College of Surgeons of England/ British Association of Urological Surgeons first robotic fellowship training programme in the UK. All patients had biopsy-proven adenocarcinoma of the prostate. Clinical data, prostate biopsies and staging investigations were reviewed at the uro-oncology multidisciplinary team meeting. All patients were seen in the outpatient clinic pre-operatively and were offered and reviewed (74%) by clinical oncologist to discuss either external beam radiotherapy or bracytherapy as an alternative to RRP.
All 300 patients were divided into 3 equal groups: Group 1 (Case 1-100), Group 2 (Case 101-200), and Group 3 (Case 201-300) (table 1). The mean age at the time of surgery was 60.7 years (range 41-74 years) and the mean presenting PSA at the time of diagnosis was 8.35 ng/ml (range 0.9-36 ng/ml). The D'Amico risk group classification for Group 1 to 3 is summarized in table 2.
All patients were admitted the evening before surgery and had sequential elasticated compression stockings placed. A phosphate enema was given to empty the rectum. Prophylactic broad spectrum antibiotics were given at induction of anesthesia.
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The RRP was performed by one of the 3 surgeons who are the 3 senior authors on this paper (T.L., G.B. or J.A.). The fellows who are the first 2 authors (N.V., C.B.) were also trained on the console. All RRP were performed using the four arm da Vinci ® robotic system. The primary surgeons (J.A.) was trained in advanced laparoscopic surgery with in a fellowship programme, the additional 2 surgeons (T.L., G.B.) have performed a large number of laparoscopic and open uro-oncological procedures. All 3 surgeons had previous experience in laparoscopic, open and perineal RP. Tableside assistance was performed by one of four registrars on the rotation at the institution and none of the registrars had previous experience in robotic surgery or assisting in robotic surgery previously.
Patients received a standard general anesthetic consisting of fentanyl 100 mg, midazolam 2 mg and propofol induction and intubation facilitated by Atracurium. In addition paracetamol 1 g, ketorolac 30 mg, ondansetrom 4 mg and dexamethasone 6.6 mg were given. Anesthesia was maintained with oxygen, air and Desflurane through a circle system and positive pressure ventilation. Muscle relaxation was maintained with Atracurium infusion. The caudal block administered contained 40 ml 0.25% bupivicaine, 150 mg clonidine and 100 mg fentanyl. Bupivacaine 0.5% 20 ml were infiltrated to the skin wounds at the end of the operation. Regular paracetomol was prescribed postoperatively and ketorolac 30 mg im and oramorph 20 mg and cyclizine were available on an as required basis. A clear view of the face and vigilance in positioning are important preventative measures. The patient is transferred onto a non-slip gel mat on the operating table ( fig. 1 ). Prior to this a sheet is folded around a head pillow and then secured under the gel mat to stop the pillow from moving. A second gel mat is placed transversely across the table at mid arm level. This is used to wrap over the patients arms and under the torso to secure the arms during surgery. This configuration prevents the patient from slipping when in the steep Trendelenburg position and spreads the pressure across all contact points, rather than being focused at the shoulders. It is important to ensure all intravenous cannulae are well padded to protect the skin, connections are secure and fluid is running freely as access is limited during surgery.
A standard six-port placement and transperitoneal approach was used in all cases. A 1/0 V-Loc™ barbed unidirectional polyglyconate suture was used to control the dorsal venous complex (DVC). However, in the last 100 cases (Group 3) the DVC was cut open and over-sewn with 1/0 V-Loc™ barbed unidirectional polyglyconate suture. From case 46 onwards the periurethral tissue was suspended to the periosteum of the pubic bone as described by Patel et al. [15] . Antregrade dissection was performed from the bladder neck using monopolar scissors and 5 mm titanium clips for the control of small vessels. A combination of interfascial and intrafascial nerve spare techniques were used depending on the patients pre-operative paramaters and D'Amico risk group stratification. The patient pre-operative sexual function was also considered before performing either a nerve spare or a wide local excision. The vesico-urethral anastomosis was performed using two 3/0 V-Loc™ barbed unidirectional polyglyconate sutures which were used to form a bidirectional suture for continuous anastomosis. As a part of the anastomosis, a total anatomical repair was performed incorporating the Denovilliers fascia posteriorly and the DVC anteriorly to form a single continuous layer as described by Sengupta et al. [16] . An 18 Fr Foleys catheter was inserted prior to the completion of the anastomosis. A leak test was routinely performed with 100 ml of saline to check the integrity of the anastomosis. Pelvic lymph node dissection was performed in all high risk D'Amico patients.
Post-operatively all patients received 28 days of low molecular weight heparin. TED stockings were routinely used and patients were encouraged to mobilize from postoperative day 1. The drain was removed when the output was < 150 ml post-operatively and we aimed to discharge all patients when the patient was mobile, tolerating solid food and had the drain removed. At the beginning of our series the patients had the catheter removed at day 14 but as the series progressed this decreased to 7 days. A cystogram was only organized if there were concerns about leak. Following catheter removal, all patients were seen by the continence advisor and instructed in pelvic floor exercise technique.
All pathology specimens were analyzed at the central pathology meeting and discussed at the regional urology multidisciplinary team meeting.
Peri-operative data collected included length of operative time, weight of prostate specimen, estimated blood loss, transfusion rate, post-operative length of hospital stay, duration of catheterisation and PSM rates. All complications occurring within the first 100 days of surgery were recorded, defined and graded using the Clavien-Dindo system [17] . Patients were reviewed in clinic 6 weeks following surgery, every 3 months thereafter for the first year and 6-monthly until year 5 with PSA measurements. Continence was defined as being pad free. Potency was defined as an erection sufficient for vaginal penetration with or without the assistance of a PDE5 inhibitor.
Prior to commencing RRP in our department, Surgeon 1 (J.A.) was proficient in upper tract laparoscopic surgery and was regularly performing laparoscopic nephrectomy, nephro-ureterectomy, pyeloplasty, prostatecetomy and had completed an advanced laparoscopic and uro-oncology fellowship. On the establishment of the RRP service in the unit Surgeon 1 (J.A.) was mentored by national UK experts (Mr. Ogden, Mr. Anderson and Prof. Dasgupta) for the first 10 cases.
The majority of our first 100 cases (Group 1) were performed by Surgeon 1 (Mr. Adshead) was assisted by surgeon 2 (Mr. Boustead). For the second 100 cases (Group 2), Surgeon 1 trained Surgeon 2 in a modular fashion until Surgeon 2 was competent in all steps of RRP. For the next 100 cases (Group 3) Surgeon 2 worked semi-independently of Surgeon 1 who was available to provide assistance in particularly difficult cases. Both Surgeon 1 and 2 mentored Surgeon 3 (Mr. Lane) during the last 50 cases in Group 2. As per British Association of Urological Surgeons guidelines, prior to commencing LRP, Surgeon 2 and 3 completed 'dry' and 'wet' labs, attended live demonstration masterclasses, attended a high-volume centre of excellence as an observer and had gained experience of open and perineal prostatecetomy. The fellowship training programme was introduced in August 2011 which is now recognized by the Royal College of Surgeons of England/British Association of Urological Surgeons first robotic fellowship training programme in the UK. The initial fellow (C.B.) has trained overseas and the second fellow (N.V.) was a UK based trainee who has recently completed his structured 6-year specialist registrar rotation.
Results

Operative Parameters
The mean operative time and mean console time for the whole cohort was 224 minutes (range 95-522 minutes) and 177 minutes (range 65-450 minutes) respectively. The mean operating time for Group 1 was 272 ± 74.6 minutes, Group 2 was 228 ± 55.8 minutes and Group 3 was 171 ± 40.2 minutes (p < 0.001). The mean console time for Group 1 was 217 ± 72.6 minutes, Group 2 was 185 ± 51.7 minutes and Group 3 was 132 ± 38.7 minutes (p < 0.001).
The incidence of intraoperative blood transfusion was 2.3% (7/300). There were no conversions to open prostatectomy in the series. A summary of the intra-operative parameters is summarized in table 3.
Post-Operative Parameters
The mean length of hospital stay for the entire cohort was 2.3 days (range 1-12 days). Patients in Group 3 had a significantly shorter hospital stay than patients in Group1 (2.58 ± 1.8 vs 1.86 ± 1 days, p = 0.001). The mean duration of catheterisation improved from 11.2 ± 2.8 days in Group 1, 9.1 ± 3.5 days in Group 2 to 7.9 ± 2.9 days in Group 3 (p = 0.001). The post-operative parameters are summarized in table 4.
Post-Operative Complications
All complications occurring within the first 100 days of surgery were recorded, defined and graded using the Clavien-Dindo system (table 4) [17] . The complications were classified into Grade I-V. Grade I -required oral medication/bedside care; Grade II -required intravenous therapy, enteral feeding or transfusion; Grade III -required intubation, interventional radiology or re-operative intervention; Grade IV -required organ resection or resulted in chronic disability and Grade V -death.
The overall incidence of postoperative complications was 13% (39/300). The incidence of minor complications (Grade I-II) was 12.6% (28/300). The incidence of major complications (Grade III-V) was 4.6% (11/300). The complication rates for each group are summarized in table 5.
Final Histology and PSM Status
The histology for all cases was reported using the 2002 Tumour Node Metastasis (TNM) classification. The incidence ≤ pT2 tumors was 71.6% (222/300), pT3 tumors 26.6% (74/300) and pT4 tumors 1.6% (4/300). PSM rates improved across the 3 groups with progression through the series. The incidence of PSM in Group 1 was 22%, Group 2 was 32% and Group 3 was 25% (p = 0.02). The final histology and PSM are summarized in table 6.
Advanced tumor stage (pT3/4) and PSA levels > 10 mg/dl at diagnosis are associated with significantly higher rates of PSM (p < 0.01, 0.044 respectively). The overall PSM rate for our series was 26.7% (80/300). On comparing the 3 consecutive groups the PSM rates were 22% (Group 1), 32% (Group 2) and 26% (Group 3) respectively. However, there were a far higher number of pT3 tumors in Group 3 than in Groups 1 and 2.
Continence and Potency At a mean follow-up of 24.87 months (range 0.4-39 months), 78.6% (236/300) of patients were completely dry and pad-free. Eighteen point nine percent (55/300) of patients wore between 1 pads/day and 3% (9/300) wore 3-4 pads/day and are being monitored carefully. Of these 9 patients 3 patients are being referred for video-urodynamic assessments with a few for further treatments.
We present the erectile dysfunction data for Group 1 and 2 in view of the follow-up (n = 200). In both groups erections satisfactory for vaginal penetration and intercourse are present in 28 (15.7%) patients. Patients on PDE-5 inhibitors are able to have satisfactory intercourse in 116 (58%) patients. A further 19 (9.5%) patients used intracaversosal alprostadil injections to achieve erection. The incidence of erectile dysfunction in current series is 16.8%. Among these patients with erectile dysfunction 60% have undergone a wide local excision and 45% of these patients have pre-operative erectile dysfunction.
Discussion
This sudden rise in incidence of localized prostate cancer inevitably led to an increased demand for curative treatments. The key surgical benefits of robotic technology are to tirelessly make precise repetitive movements to move, locate and hold tools and to respond quickly to changes in commands. Robots are intended to assist rather than replace the surgeon, who retains control at all times. With the further advancement in technology surgeons continue to seek less invasive ways to perform RP with further innovations in robotic technology such as the application of nanotechnology and nanorobotics. The advantages of the multi-armed robotic telemanipulator system in terms of improved dexterity of operation of laparoscopic instruments by increasing articulation and scaling together with the three-dimensional magnified image all set in an ergonomic platform encouraged a number of centers, particularly in the USA, to apply this system to RP. It was also thought that the greater scope for telemedicine mentoring and the ability of the robot to scale surgeon movements and hence reduce unwanted movements such as tremor would widen the group of surgeons who could achieve competency at keyhole prostatectomy [18, 19] .
There are numerous studies that evaluate the learning curve of laparoscopic prostatectomy but the evidence for robotic prostatectomy is limited. Most of the current laparoscopic prostatectomy and robotic prostatectomy series is single surgeon [20] . Ours current robotic series is unique in the fact that our series is of 3 surgeons training and the establishment of a UK nationally recognized robotic fellowship program. In current literature the experience of single surgeon who has performed RP is based on 3 categories which include surgeons who were 'experienced', 'fellowship trained' or 'performed radical retropubic prostatectomies for 15 years prior to study ' [3] . The rate of PSM through a series is a key reflection of the surgeons and units progress [3, 20] . Across the studies included in the meta-analyses of positive margin rates, there was no evidence that experience contributed as a significant confounder to the results, whereas the larger case series suggested a reduction over time in positive margin rates.
In our series, the first surgeon was an experienced upper tract laparoscopist. After mentoring from expert pelvic laparoscopic surgeons, he performed the procedure independently, assisted by Surgeon 2. After 50 cases, he began training Surgeon 2 who was an experienced open radical retropubic and perineal prostatectomist. The data from Group 2 indicate that the overall results continued to improve despite the training of a second surgeon. In Group 3, a third surgeon began training when the combined experience of Surgeons 1 and 2 exceeded 200 LRP cases. Our experience shows the feasibility of training new surgeons in RRP at a relatively early stage without compromising oncological outcomes or complication rates. Careful support and mentorship allowed dissemination of this complex technique within our department whilst operative times, blood loss and complication rates all fell. The introduction of a fellowship programme had no bearing effect on patient outcome as results continued to improve.
Within our series at a mean follow-up of 36.5 months the incidence of biochemical failure and salvage treatment 2.6% (8/300). Longer follow-up is to evaluate the oncological efficacy and recurrence rates following LRP. It is probable that PSA failure and disease recurrence following LRP reduces with improved surgical experience. With further experience in RRP at our centre we are now offering high-risk D'Amico patients a RRP.
Close co-operation with our anaesthetic colleagues was vital in developing a safe RRP service. A RRP is a relatively long procedure requiring steep Trendelenburg positioning (> 30 o ) and CO 2 pneumoperitoneum which can impact adversely on normal physiology. Careful patient selection and attention to detail is key to achieving a good outcome. Important considerations such as compartment syndrome in patients undergoing a RRP have been documentation and patient positioning is crucial to prevent this catastrophic complications [21] .The increase in dead space can lead to an increase in arterial-alveolar gradient for CO 2 . The study by Kalmar et al. [24] found that the end-tidal CO 2 (ETCO 2 ) measurement can be around 1.41 kPa lower than arterial pCO 2 after 2 hours in the Trendelenburg position. Tidal volumes and respiratory rate need to be increased to prevent hypercarbia and respiratory acidosis. Intracranial pressure (ICP), cerebral blood flow and intra-ocular pressure (IOP) increase in the in the Trendelenburg position. A rise in PaCO 2 further increases ICP and IOP [23] . Surgical duration and ETCO 2 are significant predictors of increased IOP in the Trendelenburg position. Maintaining PaCO 2 within normal limits is important to prevent potentially devastating rises in ICP and IOP [22, 23] . The increased filling pressures during pneumoperitoneum and in the Trendelenburg position produced no change in left ventricular transverse areas, either systolic or diastolic. The right atrial dimension also remained unaffected.
In our patients have there blood pressure monitored with an arterial line during their RRP. Fluid restriction decreases urine production to facilitate a dry operative field. It may also reduce the amount of facial and cerebral oedema. It is difficult to accurately monitor urine output and blood loss in these patients because suction from the abdomen will contain a variable mixture of blood, urine and wash. Not all fluid will be evacuated into the suction bowls. Regular HemaCue measurements are useful if excessive blood loss is suspected [24] . Renal perfusion decreases due to a combination of raised intra-abdominal pressure and activation of the renin, aldosterone and angiotensin systems. This is associated with a decrease in urine production and deterioration in renal function. Minimising intra-abdominal pressure, duration of surgery, and ensuring adequate cardiac output help preserve renal function [22] [23] [24] .
Conclusion
A RRP is a safe procedure with low morbidity. As surgeons progress through the learning curve peri-operative parameters and oncological outcomes improve. This learning curve is not affected by the introduction of a fellowship-training programme. With appropriate support, training and mentorship RRP can be taught to other surgeons and fellows in a structured mentored modular approach while continuing to improve outcomes for patients. Using a carefully structured mentored approach, RRP can be safely introduced as a new procedure without compromising patient outcomes.
